Association of a History of Sleep Disorder With Risk of Mild Cognitive Impairment and Alzheimer’s Disease Dementia

Author:

Choe Young MinORCID,Suh Guk-HeeORCID,Kim Jee WookORCID,

Abstract

Objective We explored whether a history of sleep disorder affected a current diagnosis of cognitive impairment and clinical conversion in a non-demented elderly population.Methods Comprehensive clinical data collected as part of the Alzheimer’s Disease Neuroimaging Initiative (ADNI) was analyzed. A history of sleep disorder was recorded in the recent ADNI medical database. Standard clinical and neuropsychological tests were performed both at baseline and follow-up visit. Multiple logistic regression analysis was performed after adjusting for age, sex, education, apolipoprotein E ε4 status, vascular risk score, body mass index, Geriatric Depression Scale score, and use of sleeping pills.Results A total of 391 cognitively normal individuals, 303 with early mild cognitive impairment (MCI) and 364 with late MCI were included. Sleep disorder history was significantly associated with an increased risk of MCI but not with clinical conversion. A history of insomnia or obstructive sleep apnea (OSA) significantly increased the risk of MCI, but only an OSA history predicted progression to Alzheimer’s disease (AD) dementia.Conclusion Our findings suggest that a sleep disorder history usefully aids early detection of cognitive impairment and emphasize that such sleep disorder, particularly OSA, is important as potential target for AD prevention.

Funder

Hallym University Research

Alzheimer’s Disease Neuroimaging Initiative

Department of Defense Alzheimer’s Disease Neuroimaging Initiative

National Institute on Aging

National Institute of Biomedical Imaging and Bioengineering

AbbVie

Alzheimer’s Association

Alzheimer’s Drug Discovery Foundation

Araclon Biotech

BioClinica, Inc.

Biogen

Bristol-Myers Squibb Company

CereSpir, Inc.

Cogstate

Eisai Inc.

Elan Pharmaceuticals, Inc.

Eli Lilly and Company

EuroImmun

F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.

Fujirebio

GE Healthcare

IXICO Ltd.

; Janssen Alzheimer Immunotherapy Research & Development, LLC.

; Johnson & Johnson Pharmaceutical Research & Development LLC.

Lumosity

Lundbeck

Merck & Co., Inc.

Meso Scale Diagnostics, LLC.

NeuroRx Research

Neurotrack Technologies

Novartis Pharmaceuticals Corporation

Pfizer Inc.

Piramal Imaging

Servier

; Takeda Pharmaceutical Company

Transition Therapeutics

Canadian Institutes of Health Research

Foundation for the National Institutes of Health

Northern California Institute for Research and Education

Alzheimer’s Therapeutic Research Institute at the University of Southern California

Laboratory for Neuro Imaging at the University of Southern California

Publisher

Korean Neuropsychiatric Association

Subject

Biological Psychiatry,Psychiatry and Mental health

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3